Biosensor tech company secures $100M investment
By HME News Staff
Updated 11:11 AM CDT, Tue April 22, 2025
SAN DIEGO – Biolinq, a healthcare technology company of biosensors, has received a $100 million Series C financing led by Alpha Wave Ventures, with participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital. The funding will support Biolinq through the US regulatory approval process as the company prepares to bring the first autonomous intradermal glucose sensor to market. Biolinq’s initial product is a wearable biosensor powered by an array of tiny electrochemical sensors that measure glucose levels continuously just beneath the skin’s surface. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device,” said Rich Yang, CEO. “Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person’s metabolic health.” Biolinq’s glucose sensor patch placed on the upper forearm features a color-changing indicator light, providing users with real-time feedback to stay informed about glucose excursions. The company’s first-generation glucose sensor is designed for ease of use and reliability leveraging a biosensing platform that enables future multi-analyte sensing capabilities.
Comments